Global HPV vaccines market to triple by 2035, driven by rising cancer-prevention efforts

What happened: The global Human Papillomavirus (HPV) vaccines market is projected to grow from USD 10.88 billion in 2026 to USD 29.63 billion by 2035.

Why it matters now: Countries are expanding HPV vaccination programs amid rising cervical and throat cancer rates linked to the virus.

What changes for people: Wider access and national immunisation campaigns will bring the vaccine to more adolescents and young adults worldwide.

Who is affected: Healthcare systems, vaccine manufacturers, public-health agencies, parents and eligible age groups.

The global market for HPV vaccines is set for major expansion over the next decade, backed by aggressive cancer-prevention strategies and rising awareness of HPV’s long-term health risks.

From an estimated USD 9.73 billion in 2025, the market is expected to climb to USD 10.88 billion in 2026, before surging to USD 29.63 billion by 2035, representing a CAGR of 11.78 percent between 2026 and 2035.

What is driving this rapid growth?

1. Strong government-led vaccination programs

Countries across North America, Europe, Asia and Latin America are integrating HPV vaccines into routine adolescent immunisation schedules, often making them free or subsidised.

2. Rising burden of HPV-linked cancers

HPV is associated with:

cervical cancer

anal cancer

penile cancer

vaginal cancer

head and neck cancers

The surge in global incidence has pushed health ministries to scale up early-prevention measures.

3. Increasing public awareness

More families are seeking HPV vaccination after campaigns led by:

WHO

national cancer institutes

women’s-health organisations

global vaccine alliances

These efforts are changing perceptions around the vaccine and accelerating uptake among boys and girls.

4. Wider age-group approvals

Regulators in multiple countries now allow HPV vaccination up to age 45, increasing the potential market.

Key industry players benefiting from the growth

Major manufacturers expected to dominate the market include:

Merck & Co. (Gardasil and Gardasil 9)

GlaxoSmithKline (GSK) (Cervarix)

Expansion of production facilities and research into next-generation HPV vaccines are under way to meet escalating global demand.

Regional trends shaping the future

North America:

High coverage rates and strong awareness keep demand steady.

Asia-Pacific:

India, China, Japan and Southeast Asia are driving the fastest growth, thanks to large birth cohorts and new national vaccination rollouts.

Europe:

Government-backed school-based vaccination programs maintain consistent uptake.

Latin America & Africa:

Supported by global health partnerships that subsidise HPV vaccines for low-income regions.

Market outlook: Stable, rising and prevention-focused

Experts say the HPV vaccines market will continue expanding due to:

early-screening initiatives

increased female-health budgeting

long-term cost benefits of cancer prevention

growing acceptance of gender-neutral vaccination

By 2035, HPV vaccination could emerge as one of the largest global immunisation markets, reflecting a shift toward preventive oncology.